A Study of FT1 in Healthy Adult Volunteers

Summary

The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are: • Is FT1 safe in healthy adults? Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and active in human. Participants will * Receive one subcutaneous injection or multiple injections of FT1 or placebo according to weight. * Visit the clinic for assessment.

Timeline

Start

2024-08-20

Primary completion

2025-08-08

Completion

2025-08-08

Drugs

Indications